Lemieux Bernard, Bouafia Fadhela, Thieblemont Catherine, Hequet Olivier, Arnaud Philippe, Tartas Sophie, Traulle Catherine, Salles Gilles, Coiffier Bertrand
Hematology Department, Hospices civils de Lyon, Université Claude Bernard, Pierre-Benite, France.
Hematol J. 2004;5(6):467-71. doi: 10.1038/sj.thj.6200559.
The purpose of this study was to evaluate retrospectively the effect of a second treatment with rituximab for patients who progressed after a response to a first treatment. We analysed the charts of 41 patients treated at CHU Lyon-Sud between 1997 and May 2003. Patients were treated with rituximab alone or with a combination of rituximab and chemotherapy. The overall response rate (complete and partial response) was 73% for the second treatment. The median time to progression was longer but not significant for the second treatment in comparison with the first one (15.2 versus 11.3 months, P = 0.09). The second treatment was well tolerated. Thus, a second treatment with rituximab should be considered, alone or in combination with chemotherapy, for patients who progress after a first response to rituximab.
本研究的目的是回顾性评估利妥昔单抗再次治疗对首次治疗有反应后病情进展患者的疗效。我们分析了1997年至2003年5月间在里昂南大学医院接受治疗的41例患者的病历。患者接受了单独的利妥昔单抗治疗或利妥昔单抗与化疗联合治疗。第二次治疗的总缓解率（完全缓解和部分缓解）为73%。与第一次治疗相比，第二次治疗的疾病进展中位时间更长，但差异无统计学意义（15.2个月对11.3个月，P = 0.09）。第二次治疗耐受性良好。因此，对于首次使用利妥昔单抗有反应后病情进展的患者，应考虑单独或联合化疗使用利妥昔单抗进行再次治疗。
